Gerardo Capo

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

William Bensinger, Sundar Jagannath, Robert Vescio et al. · British Journal of Haematology · 2009 · 36 citations · Full text

Hematological Malignancy, Oncology, Transplantation +13

A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma

William Bensinger, Sundar Jagannath, Robert Vescio et al. · Blood · 2008 · 25 citations

The Impact of Diabetes Mellitus on Breast Cancer Outcomes: A Single Center Retrospective Study

Swaroopa Yerrabothala, Hamid Shaaban, Gerardo Capo et al. · Pathology & Oncology Research · 2013 · 18 citations

Diabetes Management, Breast Oncology, Health Policy +9

The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study

Sergio D. Bergese, Erika Puente-Poushnejad, Maria A. Antor et al. · Frontiers in Medicine · 2016 · 13 citations · Full text